U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07708285) titled 'Luvometinib in Combination With Serplulimab for NF2-Related Tumors' on July 03.
Brief Summary: This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
NF2-related Schwannomatosis
NF2
Neurofibromatosis Type 2
Vestibular Schwannoma
Menin...